Astellas, Boehringer Sue Impax For Prostate Drug Patent Infringement
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Moving in concert with the Japanese government's policy to toughen intellectual property rights protection, Astellas, jointly with Boehringer Ingelheim Pharmaceuticals, filed a patent infringement lawsuit in the United States against Impax Laboratories for Astellas' prostate treatment drug, the company announced July 22